Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP771745.RAx9iPMAMjKlsCrB04vMMmBGMEY4WcZwe0E3f9-mS8qog130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP771745.RAx9iPMAMjKlsCrB04vMMmBGMEY4WcZwe0E3f9-mS8qog130_assertion type Assertion NP771745.RAx9iPMAMjKlsCrB04vMMmBGMEY4WcZwe0E3f9-mS8qog130_head.
- NP771745.RAx9iPMAMjKlsCrB04vMMmBGMEY4WcZwe0E3f9-mS8qog130_assertion description "[We conducted a clinical trial to evaluate bevacizumab, a neutralizing antibody against vascular endothelial growth factor, in patients with metastatic renal-cell carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP771745.RAx9iPMAMjKlsCrB04vMMmBGMEY4WcZwe0E3f9-mS8qog130_provenance.
- NP771745.RAx9iPMAMjKlsCrB04vMMmBGMEY4WcZwe0E3f9-mS8qog130_assertion evidence source_evidence_literature NP771745.RAx9iPMAMjKlsCrB04vMMmBGMEY4WcZwe0E3f9-mS8qog130_provenance.
- NP771745.RAx9iPMAMjKlsCrB04vMMmBGMEY4WcZwe0E3f9-mS8qog130_assertion SIO_000772 12890841 NP771745.RAx9iPMAMjKlsCrB04vMMmBGMEY4WcZwe0E3f9-mS8qog130_provenance.
- NP771745.RAx9iPMAMjKlsCrB04vMMmBGMEY4WcZwe0E3f9-mS8qog130_assertion wasDerivedFrom befree-20150227 NP771745.RAx9iPMAMjKlsCrB04vMMmBGMEY4WcZwe0E3f9-mS8qog130_provenance.
- NP771745.RAx9iPMAMjKlsCrB04vMMmBGMEY4WcZwe0E3f9-mS8qog130_assertion wasGeneratedBy ECO_0000203 NP771745.RAx9iPMAMjKlsCrB04vMMmBGMEY4WcZwe0E3f9-mS8qog130_provenance.